Colorectal Cancer Diagnostics Market
Description
Colorectal Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Diagnostic Kits & Assays, Instruments & Systems, Reagents & Consumables), By Test Type, By Cancer Type, By End-use, By Region, And Segment Forecasts, 2026 - 2033
Colorectal Cancer Diagnostics Market Summary
The global colorectal cancer diagnostics market size was estimated at USD 9.53 billion in 2025 and is projected to reach USD 14.39 billion by 2033, growing at a CAGR of 5.34% from 2026 to 2033. The industry is driven by the increasing incidence of colorectal cancer, rising demand for early and accurate diagnostic solutions, growing adoption of non-invasive screening methods, and advancements in molecular and genomic diagnostic technologies.
The rising prevalence of colorectal cancer, particularly among younger adults, is further increasing the need for effective screening and diagnostic approaches. In addition, the growing financial burden associated with colorectal cancer treatment is driving demand for more cost-effective and efficient diagnostic solutions. Technological advancements in genomics and molecular diagnostics are also improving the accuracy and personalization of colorectal cancer detection. Moreover, the increasing emphasis on early disease detection and preventive healthcare is encouraging the adoption of innovative colorectal cancer diagnostic technologies.
The global burden of colorectal cancer (CRC) continues to increase, making it among the most commonly diagnosed cancers worldwide. According to estimates from the International Agency for Research on Cancer (IARC) and the GLOBOCAN study published in Gut, approximately 1.9 million new CRC cases and over 930,000 deaths were reported globally in 2020. Projections indicate that the global burden could rise to around 3.2 million new cases and 1.6 million deaths annually by 2040. This increasing disease prevalence is a significant factor driving demand for improved screening, diagnostic, and treatment solutions. CRC is considered one of the most preventable cancers when detected early, particularly through the identification and removal of precancerous lesions. However, the growing incidence in transitioning economies and among younger adults highlights the need for improved awareness, preventive strategies, and broader screening initiatives to reduce future disease burden and mortality.
Early detection plays a critical role in improving survival outcomes, as colorectal cancer is highly treatable when diagnosed at an early stage. Timely diagnosis not only improves patient survival rates but also significantly reduces treatment costs compared to advanced-stage disease management. Consequently, the increasing emphasis on early detection is accelerating the adoption of advanced screening technologies. Non-invasive, at-home stool-based screening tests such as fecal immunochemical tests (FIT) and stool DNA tests (e.g., Cologuard) are gaining widespread acceptance due to their convenience and effectiveness, thereby improving patient compliance with screening programs. From an economic perspective, the treatment of late-stage colorectal cancer can cost up to three times more than early-stage treatment, strengthening the value of large-scale screening programs and preventive diagnostics.
Global Colorectal Cancer Diagnostic Market Report Segmentation
This report forecasts revenue growth at the global, regional and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global colorectal cancer diagnostics market report on the basis of product, test type, cancer type, end-use, and region:
Colorectal Cancer Diagnostics Market Summary
The global colorectal cancer diagnostics market size was estimated at USD 9.53 billion in 2025 and is projected to reach USD 14.39 billion by 2033, growing at a CAGR of 5.34% from 2026 to 2033. The industry is driven by the increasing incidence of colorectal cancer, rising demand for early and accurate diagnostic solutions, growing adoption of non-invasive screening methods, and advancements in molecular and genomic diagnostic technologies.
The rising prevalence of colorectal cancer, particularly among younger adults, is further increasing the need for effective screening and diagnostic approaches. In addition, the growing financial burden associated with colorectal cancer treatment is driving demand for more cost-effective and efficient diagnostic solutions. Technological advancements in genomics and molecular diagnostics are also improving the accuracy and personalization of colorectal cancer detection. Moreover, the increasing emphasis on early disease detection and preventive healthcare is encouraging the adoption of innovative colorectal cancer diagnostic technologies.
The global burden of colorectal cancer (CRC) continues to increase, making it among the most commonly diagnosed cancers worldwide. According to estimates from the International Agency for Research on Cancer (IARC) and the GLOBOCAN study published in Gut, approximately 1.9 million new CRC cases and over 930,000 deaths were reported globally in 2020. Projections indicate that the global burden could rise to around 3.2 million new cases and 1.6 million deaths annually by 2040. This increasing disease prevalence is a significant factor driving demand for improved screening, diagnostic, and treatment solutions. CRC is considered one of the most preventable cancers when detected early, particularly through the identification and removal of precancerous lesions. However, the growing incidence in transitioning economies and among younger adults highlights the need for improved awareness, preventive strategies, and broader screening initiatives to reduce future disease burden and mortality.
Early detection plays a critical role in improving survival outcomes, as colorectal cancer is highly treatable when diagnosed at an early stage. Timely diagnosis not only improves patient survival rates but also significantly reduces treatment costs compared to advanced-stage disease management. Consequently, the increasing emphasis on early detection is accelerating the adoption of advanced screening technologies. Non-invasive, at-home stool-based screening tests such as fecal immunochemical tests (FIT) and stool DNA tests (e.g., Cologuard) are gaining widespread acceptance due to their convenience and effectiveness, thereby improving patient compliance with screening programs. From an economic perspective, the treatment of late-stage colorectal cancer can cost up to three times more than early-stage treatment, strengthening the value of large-scale screening programs and preventive diagnostics.
Global Colorectal Cancer Diagnostic Market Report Segmentation
This report forecasts revenue growth at the global, regional and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global colorectal cancer diagnostics market report on the basis of product, test type, cancer type, end-use, and region:
- Product Outlook (Revenue, USD Billion, 2021 - 2033)
- Diagnostic Kits & Assays
- Instruments & Systems
- Reagent & Consumables
- Others
- Test Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Stool-Based Tests
- Endoscopy-Based Tests
- Imaging Tests
- Blood-Based Tests
- Others
- Cancer Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Adenocarcinoma
- Others
- End Use Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospitals Laboratories
- Diagnostic Laboratories / Diagnostic Centers
- Cancer Research Institutes
- Ambulatory Surgical Centers
- Academic Institutes
- Others
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Norway
- Denmark
- Sweden
- Norway
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Rest of Middle East
Table of Contents
120 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.2.1. Product Type
- 1.2.2. Product
- 1.2.3. Cancer Type
- 1.2.4. End-use
- 1.2.5. Regional Scope
- 1.2.6. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Regional outlook
- 2.4. Competitive Insights
- Chapter 3. Colorectal Cancer Diagnostics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising global incidence of colorectal cancer
- 3.2.1.2. Government initiatives increasing public-health-awareness
- 3.2.1.3. Increasing awareness of early diagnostics
- 3.2.1.4. Innovation in genomics-rise in demand for noninvasive screening
- 3.2.1.5. Advancement in molecular diagnostics technological advancements next generation sequencing
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High cost of advanced diagnostic procedures
- 3.2.2.2. Limited screening awareness in some regions
- 3.3. Colorectal Cancer Diagnostics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
- Chapter 4. Colorectal Cancer Diagnostics Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Colorectal Cancer Diagnostics Market: Product Movement Analysis
- 4.3. Colorectal Cancer Diagnostics Market by Product Outlook (USD Billion)
- 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 4.5. Diagnostic Kits & Assays
- 4.5.1. Diagnostic Kits and Assays Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Instruments & Systems
- 4.6.1. Instruments and Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7. Reagents & Consumables
- 4.7.1. Reagents & Consumables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.8. Others
- 4.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Colorectal Cancer Diagnostics Market: Test Type Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Colorectal Cancer Diagnostics Market: Test Type Movement Analysis
- 5.3. Colorectal Cancer Diagnostics Market by Test Type Outlook (USD Million)
- 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 5.5. Stool-Based Tests
- 5.5.1. Stool-Based Tests Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Endoscopy-Based Tests
- 5.6.1. Endoscopy-Based Tests Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.7. Imaging Tests
- 5.7.1. Imaging Tests Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.8. Blood-Based Tests
- 5.8.1. Blood Based Tests Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.9. Other Tests
- 5.9.1. Other Tests Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Colorectal Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Colorectal Cancer Diagnostics Market: Cancer Type Movement Analysis
- 6.3. Colorectal Cancer Diagnostics Market by Cancer Type Outlook (USD Million)
- 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 6.5. Adenocarcinoma
- 6.5.1. Adenocarcinoma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Others
- 6.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Colorectal Cancer Diagnostics Market: End-use Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Colorectal Cancer Diagnostics Market: End-use Movement Analysis
- 7.3. Colorectal Cancer Diagnostics Market by End-use Outlook (USD Million)
- 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 7.5. Hospital Laboratories
- 7.5.1. Hospital Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Diagnostic Laboratories / Diagnostic Centers
- 7.6.1. Diagnostic Laboratories / Diagnostic Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Cancer Research Institutes
- 7.7.1. Cancer Research Institutes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Ambulatory Surgical Centers
- 7.8.1. Ambulatory Surgical Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.9. Academic Institutes
- 7.9.1. Academic Institutes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.10. Others
- 7.10.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Colorectal Cancer Diagnostics Market: Regional Estimates & Trend Analysis
- 8.1. Regional Dashboard
- 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 8.3. North America
- 8.3.1. U.S.
- 8.3.1.1. Key country dynamics
- 8.3.1.2. Regulatory framework/ reimbursement structure
- 8.3.1.3. Competitive scenario
- 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.2. Canada
- 8.3.2.1. Key country dynamics
- 8.3.2.2. Regulatory framework/ reimbursement structure
- 8.3.2.3. Competitive scenario
- 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.3. Mexico
- 8.3.3.1. Key country dynamics
- 8.3.3.2. Regulatory framework/ reimbursement structure
- 8.3.3.3. Competitive scenario
- 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4. Europe
- 8.4.1. UK
- 8.4.1.1. Key country dynamics
- 8.4.1.2. Regulatory framework/ reimbursement structure
- 8.4.1.3. Competitive scenario
- 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.2. Germany
- 8.4.2.1. Key country dynamics
- 8.4.2.2. Regulatory framework/ reimbursement structure
- 8.4.2.3. Competitive scenario
- 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.3. France
- 8.4.3.1. Key country dynamics
- 8.4.3.2. Regulatory framework/ reimbursement structure
- 8.4.3.3. Competitive scenario
- 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.4. Italy
- 8.4.4.1. Key country dynamics
- 8.4.4.2. Regulatory framework/ reimbursement structure
- 8.4.4.3. Competitive scenario
- 8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.5. Spain
- 8.4.5.1. Key country dynamics
- 8.4.5.2. Regulatory framework/ reimbursement structure
- 8.4.5.3. Competitive scenario
- 8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.6. Norway
- 8.4.6.1. Key country dynamics
- 8.4.6.2. Regulatory framework/ reimbursement structure
- 8.4.6.3. Competitive scenario
- 8.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.7. Sweden
- 8.4.7.1. Key country dynamics
- 8.4.7.2. Regulatory framework/ reimbursement structure
- 8.4.7.3. Competitive scenario
- 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.8. Denmark
- 8.4.8.1. Key country dynamics
- 8.4.8.2. Regulatory framework/ reimbursement structure
- 8.4.8.3. Competitive scenario
- 8.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.9. Rest of Europe
- 8.4.9.1. Key country dynamics
- 8.4.9.2. Regulatory framework/ reimbursement structure
- 8.4.9.3. Competitive scenario
- 8.4.9.4. Rest of Europe market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5. Asia Pacific
- 8.5.1. Japan
- 8.5.1.1. Key country dynamics
- 8.5.1.2. Regulatory framework/ reimbursement structure
- 8.5.1.3. Competitive scenario
- 8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.2. China
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Regulatory framework/ reimbursement structure
- 8.5.2.3. Competitive scenario
- 8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.3. India
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Regulatory framework/ reimbursement structure
- 8.5.3.3. Competitive scenario
- 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.4. Australia
- 8.5.4.1. Key country dynamics
- 8.5.4.2. Regulatory framework/ reimbursement structure
- 8.5.4.3. Competitive scenario
- 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.5. South Korea
- 8.5.5.1. Key country dynamics
- 8.5.5.2. Regulatory framework/ reimbursement structure
- 8.5.5.3. Competitive scenario
- 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.6. Thailand
- 8.5.6.1. Key country dynamics
- 8.5.6.2. Regulatory framework/ reimbursement structure
- 8.5.6.3. Competitive scenario
- 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.7. Rest of Asia Pacific
- 8.5.7.1. Key country dynamics
- 8.5.7.2. Regulatory framework/ reimbursement structure
- 8.5.7.3. Competitive scenario
- 8.5.7.4. Rest of Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6. Latin America
- 8.6.1. Brazil
- 8.6.1.1. Key country dynamics
- 8.6.1.2. Regulatory framework/ reimbursement structure
- 8.6.1.3. Competitive scenario
- 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.2. Argentina
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Regulatory framework/ reimbursement structure
- 8.6.2.3. Competitive scenario
- 8.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.3. Rest of Latin America
- 8.6.3.1. Key country dynamics
- 8.6.3.2. Regulatory framework/ reimbursement structure
- 8.6.3.3. Competitive scenario
- 8.6.3.4. Rest of Latin America market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7. MEA
- 8.7.1. South Africa
- 8.7.1.1. Key country dynamics
- 8.7.1.2. Regulatory framework/ reimbursement structure
- 8.7.1.3. Competitive scenario
- 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.2. Saudi Arabia
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Regulatory framework/ reimbursement structure
- 8.7.2.3. Competitive scenario
- 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.3. UAE
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Regulatory framework/ reimbursement structure
- 8.7.3.3. Competitive scenario
- 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.4. Kuwait
- 8.7.4.1. Key country dynamics
- 8.7.4.2. Regulatory framework/ reimbursement structure
- 8.7.4.3. Competitive scenario
- 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.5. Rest of MEA
- 8.7.5.1. Key country dynamics
- 8.7.5.2. Regulatory framework/ reimbursement structure
- 8.7.5.3. Competitive scenario
- 8.7.5.4. Rest of MEA market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 9. Competitive Landscape
- 9.1. Market Participant Categorization
- 9.2. Recent Developments & Impact Analysis by Key Market Participants
- 9.3. Company Market Share Analysis, 2025
- 9.4. Key Company Profiles
- 9.4.1. Exact Sciences Corporation
- 9.4.1.1. Company overview
- 9.4.1.2. Financial performance
- 9.4.1.3. Product benchmarking
- 9.4.1.4. Strategic initiatives
- 9.4.2. F. Hoffmann-La Roche Ltd
- 9.4.2.1. Company overview
- 9.4.2.2. Financial performance
- 9.4.2.3. Product benchmarking
- 9.4.2.4. Strategic initiatives
- 9.4.3. Abbott
- 9.4.3.1. Company overview
- 9.4.3.2. Financial performance
- 9.4.3.3. Product benchmarking
- 9.4.3.4. Strategic initiatives
- 9.4.4. Danaher Corporation.
- 9.4.4.1. Company overview
- 9.4.4.2. Financial performance
- 9.4.4.3. Product benchmarking
- 9.4.4.4. Strategic initiatives
- 9.4.5. Quest Diagnostics Incorporated.
- 9.4.5.1. Company overview
- 9.4.5.2. Financial performance
- 9.4.5.3. Product benchmarking
- 9.4.5.4. Strategic initiatives
- 9.4.6. Fujifilm Holdings Corporation.
- 9.4.6.1. Company overview
- 9.4.6.2. Financial performance
- 9.4.6.3. Product benchmarking
- 9.4.6.4. Strategic initiatives
- 9.4.7. Olympus Corporation
- 9.4.7.1. Company overview
- 9.4.7.2. Financial performance
- 9.4.7.3. Product benchmarking
- 9.4.7.4. Strategic initiatives
- 9.4.8. Epigenomics AG
- 9.4.8.1. Company overview
- 9.4.8.2. Financial performance
- 9.4.8.3. Product benchmarking
- 9.4.8.4. Strategic initiatives
- 9.4.9. Eiken Chemical Co., Ltd.
- 9.4.9.1. Company overview
- 9.4.9.2. Financial performance
- 9.4.9.3. Product benchmarking
- 9.4.9.4. Strategic initiatives
- 9.4.10. Guardant Health
- 9.4.10.1. Company overview
- 9.4.10.2. Financial performance
- 9.4.10.3. Product benchmarking
- 9.4.10.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
